CA-TII
26.4.2021 12:42:13 CEST | Business Wire | Press release
Technology Innovation Institute (TII), the applied research pillar of Advanced Technology Research Council (ATRC), today announced that its Quantum Research Centre (QRC) has developed the first simulation version of 'Qibo', a versatile open-source quantum computing programming framework, in collaboration with researchers from around the world.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210426005389/en/
The development follows a series of rapid announcements at TII since the first ATRC board meeting in August 2020.
TII strives to create innovation for a better world. The development of an open-source programming framework will have compelling benefits for the global research community.
Qibo is designed to support quantum algorithms across different computer systems, including support to hardware accelerators such as graphics processing units (GPUs) and multiple quantum devices. This versatility makes Qibo easy to use for quantum programming and accelerates research and applications. Written in programming languages such as Python and C/C++, Qibo is the entry point for a full stack programming platform, able to run quantum algorithms across different quantum computers and simulators.
Qibo is a joint project by Quantum Research Centre; Qilimanjaro Quantum Tech, the Barcelona-based quantum computing company; and researchers at other global centres. TII’s Quantum Research Centre team is led by Chief Researcher Prof José Ignacio Latorre. The first release of Qibo was published in September 2020, with the final version set for launch within the next two years.
Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of Advanced Technology Research Council (ATRC), said: “The fact that Qibo is open-source will be a significant advantage to the world of programming and marks a major contribution to the research community and the advancement of scientific inquiry. Initial benchmark studies that show Qibo outperforming other computing languages is a clear indication of the quality of research currently being undertaken at Quantum Research Centre at Technology Innovation Institute."
Prof José Ignacio Latorre, Chief Researcher at Quantum Research Centre, said: “We are committed to innovation that transcends boundaries. The quantum advantage in computing will offer notable benefits to broader society, ranging from life-sciences, artificial intelligence, and finance.”
QRC is one of seven initial dedicated research centres that are part of TII. The Qibo code published in the research paper can be accessed via a GitHub link [https://qibo.science/ ].
About Technology Innovation Institute (TII)
Technology Innovation Institute (TII) is the dedicated ‘applied research’ pillar of Advanced Technology Research Council (ATRC). TII is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem reinforcing Abu Dhabi and the UAE’s status as a global hub for innovation.
For more information, visit www.tii.ae
About Quantum Research Centre (QRC)
Quantum Research Centre – at Technology Innovation Institute (TII) – has been created to develop world-class quantum-theoretical and experimental research by building and operating the first quantum computer in the MENA region while advancing quantum communications and quantum sensors. The Centre aims to develop pioneering technologies backed by the expertise of an international team of leading researchers, dedicated to achieving a ‘Quantum Advantage’ which will transform the power and scope of computers.
For more information, visit https://quantum.tii.ae/
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter:
https://twitter.com/TIIuae
Instagram:
https://www.instagram.com/tiiuae/
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210426005389/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom